

# PHARMACY POLICY STATEMENT

## Indiana Medicaid

<b>DRUG NAME</b>	<b>Jynarque (tolvaptan)</b>
BENEFIT TYPE	Pharmacy
	Prior Authorization Required

Jynarque, initially approved by the FDA in 2018, is a selective vasopressin V2-receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney > BDC 55.27f\*EMg)8 refo0.8 06q279.58 611.03 296.38 12.8 reW\*nBT/F2 11.2 60 G[(> BDC 55.27f\*EMg)-142 79

